Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Y320 suppresses non-small cell lung cancer growth by triggering autophagy-dependent pyroptosis through ubiquitin/proteasome-mediated c-FLIP degradation.

European journal of pharmacology·2026
Same author

Combining Online HPLC-ABTS Screening With Machine Learning to Predict the Bioactivity of Antioxidant Components in Pandani Tectorii Radix et Rhizoma.

Biomedical chromatography : BMC·2026
Same author

Application of small interfering RNAs and drug combination for pancreatic cancer therapy.

Journal of drug targeting·2026
Same author

Development and validation of a machine learning model to predict early recurrence after surgery in NSCLC patients.

Scientific reports·2025
Same author

Heterologous Expression of the Fellutanine Biosynthetic Gene Cluster and Characterization of the Dual Prenylation of cyclo(l-Trp-l-Trp) by a Single DMATS Enzyme.

Journal of natural products·2025
Same author

YKL-06-061 exerts antitumor effect through G1/S phase arrest by downregulating c-Myc and inhibition of metastasis via SIK1 upregulation in pancreatic cancer.

Anti-cancer drugs·2024

Related Experiment Video

Updated: Jun 4, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

[Progress on targeting TRAIL's receptor as antitumor strategy].

Shu-Zhen Chen1

  • 1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. bjcsz@yahoo.com.cn

Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|March 1, 2011
PubMed
Summary

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis via death receptors DR4/DR5. This review explores TRAIL

Area of Science:

  • Cell biology
  • Molecular biology
  • Cancer research

Background:

  • Apoptosis, or programmed cell death, occurs via intrinsic and extrinsic pathways.
  • The extrinsic pathway involves death receptors and ligands, crucial for cellular homeostasis and eliminating damaged cells.

Purpose of the Study:

  • To review the characteristics of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and its receptors.
  • To elucidate the mechanism of TRAIL-induced apoptosis.
  • To examine the role of death receptors in cancer and the therapeutic potential of the TRAIL pathway.

Main Methods:

  • Literature review of scientific articles on TRAIL signaling.
  • Analysis of the molecular mechanisms of TRAIL-induced apoptosis.
  • Review of studies on death receptor distribution in various cancers.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Screening Ion Channels in Cancer Cells
06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Related Experiment Videos

Last Updated: Jun 4, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Screening Ion Channels in Cancer Cells
06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Main Results:

  • TRAIL induces apoptosis through binding to death receptors DR4 and DR5.
  • Differential expression of DR4 and DR5 is observed in various cancer types.
  • TRAIL pathway activation presents a promising strategy for cancer therapy.

Conclusions:

  • TRAIL-mediated apoptosis is a key component of the extrinsic apoptotic pathway.
  • Targeting the TRAIL signaling pathway offers a potential therapeutic avenue for cancer treatment.
  • Further research into TRAIL receptor distribution and drug development is warranted for effective cancer therapy.